License Agreement for Use of the UMLS® Metathesaurus®

This Agreement is made by and between the National Library of Medicine, Department of Health and Human Services (hereinafter referred to as "NLM") and the LICENSEE.

WHEREAS, the NLM was established by statute in order to assist the advancement of medical and related sciences, and to aid the dissemination and exchange of scientific and other information important to the progress of medicine and to the public health (section 465 of the Public Health Service Act, as amended (42 U.S.C. section 286)), and to carry out this purpose has been authorized to develop the Unified Medical Language System® (UMLS) to facilitate the retrieval and integration of machine-readable biomedical information from disparate sources;

WHEREAS, the NLM's UMLS project has produced the UMLS Metathesaurus, a machine-readable vocabulary knowledge source, that is useful in a variety of settings;

WHEREAS, the LICENSEE is willing to use the UMLS Metathesaurus at its sole risk and at no expense to NLM, which will result in information useful to NLM, may provide immediate improvements in biomedical information transfer to segments of the biomedical community, and is consistent with NLM's statutory functions,

NOW THEREFORE, it is mutually agreed as follows:

1. The NLM hereby grants a nonexclusive, non-transferable right to LICENSEE to use the UMLS Metathesaurus and incorporate its content in any computer applications or systems designed to improve access to biomedical information of any type subject to the restrictions in other provisions of this Agreement. The names and addresses of licensees authorized to use the UMLS products are public information.

2. No charges, usage fees, or royalties will be paid to NLM.

3. LICENSEE is prohibited from distributing the UMLS Metathesaurus or subsets of it, including individual vocabulary sources within the Metathesaurus, except (a) as an integral part of computer applications developed by LICENSEE for a purpose other than redistribution of vocabulary sources contained in the UMLS Metathesaurus and (b) if permitted by paragraph 12 of this agreement.

4. LICENSEE agrees to inform NLM prior to distributing any application(s) in which it is using the UMLS Metathesaurus and is encouraged to inform NLM of any difficulties encountered in using the UMLS Metathesaurus, and changes or enhancements to the UMLS Metathesaurus that would make it more useful to LICENSEE and its user groups.

5. Within 30 days of the end of any calendar year in which LICENSEE makes use of the UMLS Metathesaurus, LICENSEE agrees to provide NLM with a brief report on the usefulness of the UMLS Metathesaurus in general and, if applicable, on the usefulness of CPT in the UMLS format in particular. LICENSEE is strongly encouraged to submit to NLM locally developed extensions to the UMLS Metathesaurus that are potentially useful to other UMLS users for consideration for potential inclusion in the UMLS Metathesaurus.

6. NLM represents that the data provided under this Agreement were formatted with a reasonable standard of care, but makes no warranties express or implied, including no warranty of merchantability or fitness for particular purpose, regarding the accuracy or completeness of the data or that the machine-readable copy is error free. Therefore, LICENSEE agrees to hold NLM, the Government, and any organization contributing a vocabulary
source to the UMLS Metathesaurus free from any liability resulting from errors in terminology or other data or on
the machine-readable copy. NLM and such other organizations disclaim any liability for any consequences due to
use, misuse, or interpretation of information contained or not contained in the UMLS Metathesaurus.

7. NLM represents that its ability to continue to include certain vocabulary sources within the UMLS Metathesaurus
is dependent on continuing contractual relations or agreements with the copyright holders for these vocabulary
sources. Therefore, LICENSEE agrees to hold NLM and the individual copyright holder free from any liability
resulting from the removal of any vocabulary source from future editions of the UMLS Metathesaurus.

8. NLM reserves the right to change the type and format of its machine-readable data. NLM agrees to inform
LICENSEE of any changes to the format of the UMLS Metathesaurus, EXCEPT the addition of entirely new data
elements to the Metathesaurus, at least 90 days before the data are distributed.

9. The presence in the UMLS Metathesaurus of vocabulary or data produced by organizations other than NLM does
not imply any endorsement of the UMLS Metathesaurus by these organizations.

10. LICENSEE shall acknowledge NLM as its source of the UMLS Metathesaurus, citing the year and version
number, in a suitable and customary manner but may not in any way indicate or imply that NLM or any of the
organizations whose vocabulary sources are included in the UMLS has endorsed LICENSEE or its products.

11. Some of the Material in the UMLS Metathesaurus is from copyrighted sources. If LICENSEE uses any material
from copyrighted sources from the UMLS Metathesaurus:

a) the LICENSEE is required to display in full, prior to providing user access to the Metathesaurus or any of the
vocabulary sources within the UMLS, the following wording in order that its users be made aware of these
copyright constraints:

"Some material in the UMLS Metathesaurus is from copyrighted sources of the respective copyright holders.
Users of the UMLS Metathesaurus are solely responsible for compliance with any copyright, patent or trademark
restrictions and are referred to the copyright, patent or trademark notices appearing in the original sources, all of
which are hereby incorporated by reference."


to display a list of all of the vocabularies contained within the UMLS Metathesaurus that are used in the
LICENSEE's application; and to indicate for each vocabulary any appropriate copyright notice and whether the
entire contents are present or only a portion of it.

b) the LICENSEE is prohibited from altering UMLS and other vocabulary source content contained within the
UMLS Metathesaurus, but may include content from other sources in applications that also contain content from
the UMLS Metathesaurus. The LICENSEE may not imply in any way that data from other sources is part of the
UMLS Metathesaurus or of any of its vocabulary sources.

c) the LICENSEE is required to include in its applications identifiers from the UMLS Metathesaurus such that the
original source vocabularies for any data obtained from the UMLS Metathesaurus can be determined by reference
to a complete version of the UMLS Metathesaurus.

12. For material in the UMLS Metathesaurus obtained from some sources additional restrictions on LICENSEE's use
may apply. The categories of additional restrictions are described below. The list of UMLS Metathesaurus
Vocabulary Sources, which is part of this Agreement and is updated when each version of the Metathesaurus is
released, indicates the category of additional restrictions, if any, that apply to each vocabulary source.

LICENSEE should contact the copyright holder directly to discuss uses of a source vocabulary beyond those
allowed under this license agreement. If LICENSEE or LICENSEE's end user has a separate agreement with the
copyright holder for use of a UMLS Metathesaurus source vocabulary, LICENSEE or LICENSEE's end user may
use vocabulary source content obtained from the UMLS Metathesaurus in accordance with the terms of the
12. 1.

LICENSEE is prohibited from translating the vocabulary source into another language or from producing other derivative works based on this single vocabulary source.

12. 2.

All category 1 restrictions AND

LICENSEE is prohibited from using the vocabulary source in operational applications that create records or information containing data from the vocabulary source. Use for data creation research or product development is allowed.

12. 3.

LICENSEE's right to use material from the source vocabulary is restricted to internal use at the LICENSEE's site(s) for research, product development, and statistical analysis only. Internal use includes use by employees, faculty, and students of a single institution at multiple sites. Notwithstanding the foregoing, use by students is limited to doing research under the direct supervision of faculty. Internal research, product development, and statistical analysis use expressly excludes: use of material from these copyrighted sources in routine patient data creation; incorporation of material from these copyrighted sources in any publicly accessible computer-based information system or public electronic bulletin board including the Internet; publishing or translating or creating derivative works from material from these copyrighted sources; selling, leasing, licensing, or otherwise making available material from these copyrighted works to any unauthorized party; and copying for any purpose except for back up or archival purposes.

LICENSEE may be required to display special copyright, patent and/or trademark notices before displaying content from the vocabulary source. Applicable notices are included in the list of UMLS Metathesaurus Vocabulary sources, that is part of this Agreement.

12. 4.

12.4.1. LICENSEE is prohibited from translating the vocabulary source into another language or from altering the vocabulary source content.

12.4.2. LICENSEE's right to use the vocabulary source is restricted to use in the U.S. by LICENSEE's employees, contractors, faculty, students, clients, patients, or constituents within electronic systems or devices built, purchased, licensed, or used by LICENSEE for U.S. governmental purposes or for any health care, public health, research, educational, or statistical use in the U.S. Use by students is limited to research or educational activities under the direct supervision of faculty.

12.4.3. LICENSEE has the right to distribute the vocabulary source in the U.S., but only in combination with other UMLS Metathesaurus content. Further, LICENSEE's right to distribute is restricted to:

a. Electronic distribution to LICENSEE's direct U.S. affiliates, or to other U.S. entities that have signed the UMLS license, in order to facilitate use of the vocabulary for health care, public health, research, educational or statistical purposes in the U.S. only.

   i. LICENSEE must take reasonable precautions to prevent distribution of the vocabulary source to non-US entities.

   ii. LICENSEE must include in its annual report a list of all U.S. affiliates or other U.S. entities to whom
it has distributed content from the vocabulary source.

b. Distribution of encoded patient level data sets or knowledge encoded in the vocabulary source by LICENSEE to any U.S. entity for use in the U.S. only.

c. Inclusion of encoded records or content from the vocabulary source in: (1) free publicly accessible retrieval systems or (2) fee-based retrieval systems that are accessible within the U.S. only, provided that these systems do not permit users to copy or extract any significant portion of the vocabulary source.

12.4.4. DEFINITIONS

a. U.S. is defined as all U.S. states, territories, and the District of Columbia; any U.S. government facility or office, whether permanent or temporary, wherever located; and access to a system in any of these locations by U.S. government employees, designated representatives or contractors, wherever located, for U.S. government purposes.

b. U.S. entity is defined as (i) for government entities, an agency or department of the U.S. Government, (ii) for corporations, as a corporation incorporated and operating in the U.S.; and (iii) for other entities as an entity organized under the laws of the U.S.

13. LICENSEE shall take reasonable steps to ensure that anyone who has authorized access to data or vocabulary sources from the UMLS Metathesaurus under this Agreement complies with its provisions.

14. LICENSEE and/or its end users shall be solely responsible for compliance with any copyright or other restrictions on vocabulary sources in the UMLS Metathesaurus; NLM assumes no responsibility or liability associated with the LICENSEE's (or any of the LICENSEE's users) use and/or reproduction of copyrighted material, patent or trademark violations. Anyone contemplating reproduction of all or any portion of the UMLS Metathesaurus or any of its vocabulary sources should consult legal counsel.

The holder of a copyright in any vocabulary source shall be a third party beneficiary to this agreement and shall have a right to enforce the agreement against any LICENSEE that violates any provision pertaining to that copyright holder.

15. This Agreement shall be effective until terminated by one of the parties upon 30 days written notice to the other party. LICENSEE's failure to abide by the terms of the Agreement shall be grounds for its termination. Neither the Government, its employees, or any vocabulary sources contained in the UMLS Metathesaurus shall be liable or responsible to LICENSEE in any manner whatsoever for damages of any nature whatsoever arising from the termination of this Agreement.

16. In the event that any provision of this Agreement is determined to violate any law or is unenforceable, the remainder of the Agreement shall remain in full force and effect.

Send questions, comments about the UMLS project to: custserv@nlm.nih.gov or call 1-888-FINDNLM.
APPENDIX 1

Appendix to the License Agreement for Use of the UMLS® Metathesaurus®

UMLS METATHESAURUS® SOURCE VOCABULARIES - 2021AA Edition

Appendix 1 is a listing of all sources within the current version of the Metathesaurus with an indication of any additional restrictions and notices that apply. Sources are listed in order according to the abbreviations used in the UMLS Metathesaurus files. All sources are subject to the general terms of the License for Use of the UMLS Metathesaurus. The Categories associated with each source are defined in the general license as follows:

- **Category 0** general terms of the License apply with no additional restrictions
- **Category 1** in addition to the general License terms, restrictions in Section 12.1 apply
- **Category 2** in addition to the general License terms, restrictions in Section 12.2 apply
- **Category 3** in addition to the general License terms, restrictions in Section 12.3 apply
- **Category 4** in addition to the general License terms, restrictions in Section 12.4 apply
- **Appendix 2** defines the terms of use of SNOMED CT. These terms take precedence over the general Metathesaurus license terms. Where an item is not addressed in Appendix 2 the general License terms apply.

**Additional Source Information:** Each source includes a link to additional source information, created by NLM, describing its purpose, content and use. The complete list of source documentation is available at: [http://www.nlm.nih.gov/research/umls/sourcereleasedocs/index.html](http://www.nlm.nih.gov/research/umls/sourcereleasedocs/index.html). Additional documentation may also be available from the producers of the source. Contact information is provided for each source.

**Questions Regarding Additional Permissions or License Agreements:** Questions about uses not covered by this Agreement, or other inquiries about individual sources, should be directed to the source contact.

---

AIR93 - AI/RHEUM; National Library of Medicine, Lister Hill Center; 1993; Bethesda, MD;

Contact: May Cheh; Lister Hill National Center for Biomedical Communications, National Library of Medicine; Building 38A, Room 9E902; 8600 Rockville Pike; Bethesda; MD; 20894; cheh@nlm.nih.gov;

Read more information about this source

---

ALT2009 - ABC Codes and Terminology; 9th; Albuquerque, NM; ABC Coding Solutions - Alternative Link; 2009; ENG;

**CATEGORY 3 RESTRICTIONS APPLY**

Contact: ABC Coding Solutions - Alternative Link; 6121 Indian School Road NE; Suite 131; Albuquerque; NM; United States; 87110; 1-877-621-5465; 1-505-875-0002; Legal@ABCcodes.com;

Read more information about this source

---

AOD2000 - Alcohol and Other Drug Thesaurus: A Guide to Concepts and Terminology in Substance Abuse and Addiction; 3rd. ed. [4 Volumes.]; Bethesda, MD; National Institute on Alcohol Abuse and Alcoholism (NIAAA) and Center for...
Substance Abuse Prevention (CSAP); 2000; ENG;

Contact: Nancy Winstanley; NIAAA Library c/o CSR Incorporated; 2107 Wilson Blvd., Suite 1000; Arlington, VA; 22201; 703-741-7147; e-mail: nwinstanley@csrincorporated.com;

Read more information about this source

AOT2003 - Authorized Osteopathic Thesaurus; Chevy Chase, MD; Educational Council of Osteopathic Principles of the American Association of Colleges of Osteopathic Medicine; 2004; http://www.aacom.org/InfoFor/educators/Pages/thesaurus.aspx; ENG;

Contact: Chevy Chase, MD; http://www.aacom.org/InfoFor/educators/Pages/thesaurus.aspx

Read more information about this source

ATC_2021_21_03_01 (updated) - WHO Collaborating Centre for Drug Statistics Methodology; Anatomical Therapeutic Chemical (ATC) classification system; 2021; Oslo, Norway; WHO Collaborating Centre for Drug Statistics Methodology; http://www.whocc.no/copyright_disclaimer/;

Contact: WHO Collaborating Centre for Drug Statistics Methodology; Norwegian Institute of Public Health; P.O. Box 4404 Nydalen; Oslo; Norway; 0403; +47 21 07 81 60; +47 21 07 81 46; whocc@fhi.no; http://www.whocc.no/copyright_disclaimer/

Read more information about this source

BI98 - Howard Goldberg, MD; Beth Israel OMR Clinical Problem List Vocabulary; Version 1.0; Boston, MA; Beth Israel Deaconess Medical Center; 1999; ENG;

CATEGORY 2 RESTRICTIONS APPLY

Contact: Daniel Z. Sands, M.D., M.P.H.; Clinical Systems Integration Architect; Center for Clinical Computing, Beth Israel Deaconess Medical Center, Harvard University; 330 Brookline Avenue; Boston, MA; United States; 02215; 617-667-1510; 810-592-0716; e-mail: dsands@bidmc.Harvard.edu;

Read more information about this source

CCC2_5_2018 - SabaCare, Inc.; Clinical Care Classification (CCC) System; 2.5; January 10, 2018; ENG;

CATEGORY 1 RESTRICTIONS APPLY

Contact: Dr. Virginia K. Saba; CEO & President; SabaCare, Inc.; Arlington, VA; United States; 703-521-6132; 703-521-3866; vsaba@att.net; http://www.sabacare.com/

Read more information about this source

CCPSS99 - Canonical Clinical Problem Statement System; Version 1.0; June 23, 1999; ENG; Contact: sbrown@vumclib.mc.vanderbilt.edu;

CATEGORY 3 RESTRICTIONS APPLY

Permission will be freely given for any uses and applications containing CCPSS which are not for sale - i.e. those used internally or given to others without charge.

Contact: Steven Brown, M.D.; Associate Professor, Biomedical Informatics; Eskind Biomedical Library, Vanderbilt University Medical Center; 2209 Garland Ave; Room 442; Nashville, TN; United States; 37232-8340; (615) 321-
CCS2005 - ;;Agency for Healthcare Research and Quality (AHRQ);;Clinical Classifications Software (CCS);;;;;;April 2005;;Rockville,MD;;;;; http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp;ENG;Phone: 301-594-1364.; Contact: Anne Elixhauser, Ph.D.;Senior Research Scientist;Agency for Healthcare Research and Quality;540 Gaither Road;;Rockville;MD;United States;20850;(301) 427-1411, 1-800-358-9295;(301) 594-1430;AElixhau@AHRQ.gov; Read more information about this source

CCSR_ICD10CM_2021 (new) - ;;Healthcare Cost and Utilization Project (HCUP);;Clinical Classifications Software Refined for ICD-10-CM;;;Agency for Healthcare Research and Quality (AHRQ);;October 2020;Rockville, MD;;;ENG;; Contact: ;;Agency for Healthcare Research and Quality;5600 Fishers Lane;Mail Stop 07N94A;Rockville;MD;United States;20857;1-866-290-HCUP;(301) 594-1430;hcup@ahrq.gov;https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp; Read more information about this source

CCSR_ICD10PCS_2021 (new) - ;;Healthcare Cost and Utilization Project (HCUP);;Clinical Classifications Software Refined for ICD-10-PCS;;;Agency for Healthcare Research and Quality (AHRQ);;December 2020;Rockville, MD;;;ENG;; Contact: ;;Agency for Healthcare Research and Quality;5600 Fishers Lane;Mail Stop 07N94A;Rockville;MD;United States;20857;1-866-290-HCUP;(301) 594-1430;hcup@ahrq.gov;https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp; Read more information about this source

CDT2021 - ;;;Code on Dental Procedures and Nomenclature;;;2021;Chicago, IL;American Dental Association;;;;;; CATEGORY 3 RESTRICTIONS APPLY
For CDT the following special notice must be displayed:
"For CDT only, copyright 2021 American Dental Association, all rights reserved."
Contact: Debbie Labinger;Manager, Special Accounts Senior Manager, Special Accounts and Licensing Program;American Dental Association;211 East Chicago Ave;;Chicago;IL;United States;60611-2678;312-440-7742;;LabingerD@ada.org;http://www.ada.org/; Read more information about this source

CHV2011_02 - ;;;Consumer Health Vocabulary;;;;;2011;USA;;;;ENG;; Contact: Qing Zeng, PhD;;Biomedical Informatics Department, University of Utah;26 South 2000 East Room 5775 HSEB;;Salt Lake City;UT;USA; 84112;;q.t.zeng@utah.edu; Read more information about this source

COSTAR_89-95 - ;;;Computer-Stored Ambulatory Records (COSTAR);;;;Boston, MA;Massachusetts General Hospital;1989-1995;;;;ENG;;
The UMLS Metathesaurus includes terms that were used frequently at 3 COSTAR sites in the years indicated and supplied to NLM by Massachusetts General Hospital.

Contact: G. Octo Barnett, M.D.; Laboratory of Computer Science Massachusetts General Hospital; 50 Staniford Street, 5th Floor; Boston; MA; United States; 02114; (617) 726-3939; (617) 726-8481; e-mail: Barnett.Octo@mgh.harvard.edu;

Read more information about this source

CPM2003 - Medical Entities Dictionary (CPM); New York (NY); Columbia Presbyterian Medical Center; 2003; ENG;

CATEGORY 2 RESTRICTIONS APPLY

The UMLS Metathesaurus includes a relatively small number of terms created at Columbia Presbyterian Medical Center for the MED, which also includes terms obtained from the UMLS Metathesaurus and other sources.

Contact: George Hripcsak, M.D.; Professor and Chair; Department of Biomedical Informatics, Vanderbilt Clinic VC-5; Columbia University; 622 W. 168th Street; New York; New York; USA; 10032; (212) 305-5780; (212) 305-3302; kripcsak@columbia.edu;

Read more information about this source

CPT2021 (updated) - Current Procedural Terminology (CPT); American Medical Association; 2021; Chicago, IL;

CATEGORY 3 RESTRICTIONS APPLY

The following special notice must be displayed:

"CPT™ only Copyright 2021 American Medical Association. All rights Reserved. No fee schedules, basic unit, relative values or related listings are included in CPT™. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for data contained herein.

U.S. Government Rights

This product includes CPT™ which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements."

Contact: American Medical Association; 330 N. Wabash, Suite 39300; Chicago; IL; United States; 60611; (800) 621-8335; Intellectual.Property.Services@ama-assn.org; https://www.ama-assn.org/practice-management/cpt-current-procedural-terminology;

Read more information about this source

http://www.ama-assn.org

CATEGORY 3 RESTRICTIONS APPLY

The following special notice must be displayed:

"CPT™ only Copyright 2021 American Medical Association. All rights Reserved. No fee schedules, basic unit, relative values
U.S. Government Rights

This product includes CPT™ which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements."

Contact: Dorith Brown, CPT Intellectual Property Services, American Medical Association, 515 N. State Street, Chicago, IL 60610; fax: (312)464-5762

Read more information about this source

CPT01SP - Current Procedural Terminology (CPT), Spanish Translation; Chicago; American Medical Association; 2000;
Contact: Dorith Brown; CPT Intellectual Property Services, American Medical Association; 515 N. State Street; Chicago; IL; United States; 60610; (312) 464-5762;

CATEGORY 3 RESTRICTIONS APPLY

Contact: Dorith Brown; CPT Intellectual Property Services, American Medical Association; 515 N. State Street; Chicago; IL; United States; 60610; (312) 464-5762;

Read more information about this source

CSP2006 - Computer Retrieval of Information on Scientific Projects (CRISP); Bethesda; National Institutes of Health, Division of Research Grants, Research Documentation Section; 2006;
Contact: Dorrette Finch; Director; Division of Research Documentation, ORA, OER, National Institutes of Health; 6701 Rockledge Drive; Bethesda; MD; 20892-7983; dw33v@nih.gov

Read more information about this source

CST95 - Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART); 5th ed; Rockville; U.S. Food and Drug Administration; Center for Drug Evaluation and Research; 1995;
COSTART has been superseded by the Medical Dictionary for Regulatory Activities (MedDRA) Terminology.
Contact: National Technical Information Service; http://www.ntis.gov/fcpc/cpn5580.htm

Read more information about this source

CVX_2021_01_29 (updated) - National Center for Immunization and Respiratory Diseases; CVX Code Set; Atlanta, GA; January 29, 2021;
Contact: CDC, National Center for Immunization and Respiratory Diseases Immunization Information System Support Branch - Informatics; 1600 Clifton Road; Mailstop: E-62; Atlanta; GA; United States; 30333; iisinfo@cdc.gov; http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx
Dxp94 - Dxp (An expert diagnosis program); Boston (MA); Massachusetts General Hospital; 1994;

Contact: G. Octo Barnett, M.D.; Laboratory of Computer Science, Massachusetts General Hospital; 50 Staniford Street; 5th Floor; Boston, MA; 02114; (617) 726-3939; (617) 726-8481; Barnett.Octo@mgh.harvard;

Fma4_15 - Jose Leonardo V. Mejino Jr., M.D., Cornelius Rosse, M.D., DSc.; Foundation Model of Anatomy; v4.15.0; Department of Biological Structure, University of Washington; April 2019;

Contact: Jose L. V Mejino Jr. MD; Senior Scientist, Project Director and Curator of FMA; Department of Biological Structure, University of Washington; 1959 NE Pacific Street; Box 357420; Seattle, WA; United States; 98195; 206-543-7118; 206-543-1524; fma@sig.biostr.washington.edu; http://si.washington.edu/projects/fma;

Go2020_05_02 - Gene Ontology; Gene Ontology Consortium; May 2, 2020;


Gs_2021_02_09 (updated) - Gold Standard Drug Database; 302 Knights Run Ave, Suite 800, Tampa, FL 33602; Gold Standard;

CATEGORY 3 RESTRICTIONS APPLY

Contact: RxNorm Customer Service; U.S. National Library of Medicine; 8600 Rockville Pike; Bethesda, MD; United States; 20894; (888) FIND-NLM; rxnorminfo@nlm.nih.gov; https://www.nlm.nih.gov/research/umls/rxnorm/;

Hcdt2021 (updated) - HCPCS Version of Current Dental Terminology; 2021; Baltimore, MD; Centers for Medicare & Medicaid Services;

CATEGORY 3 RESTRICTIONS APPLY

Contact: Cynthia Hake; CMS HCPCS Workgroup Chair; Centers for Medicare & Medicaid Services (CMS); 7500 Security Boulevard; Baltimore, MD; United States; 21244; 1-410-786-3404; hpcs@cms.hhs.gov; https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/index.html;

Hcpcs2021 (updated) - Healthcare Common Procedure Coding System (HCPCS); 2021; Baltimore, MD; Centers for Medicare & Medicaid Services;

The American Medical Association's CPT™ codes in HCPCS have a Source Abbreviation of HCPT04. The American Dental Association's CDT codes in HCPCS have a Source Abbreviation of HCDT4.

Contact: Cynthia Hake; CMS HCPCS Workgroup Chair; Centers for Medicare & Medicaid Services (CMS); 7500 Security Boulevard; Baltimore, MD; United States; 21244; 1-410-786-
ICD10_1998 - International Statistical Classification of Diseases and Related Health Problems (ICD-10); 10th rev.; Geneva (Switzerland); World Health Organization; 1998;

CATEGORY 3 RESTRICTIONS APPLY
Contact: Office of Publications, World Health Organization; 1211 Geneva 27; Switzerland;

Read more information about this source

ICD10_2016 - International Statistical Classification of Diseases and Related Health Problems (ICD-10); Tenth Revision; Geneva, Switzerland; World Health Organization; 2016; ENG;

CATEGORY 3 RESTRICTIONS APPLY
Contact: Office of Publications; World Health Organization; Geneva; Switzerland; 1211 Geneva 27; bookorders@who.int; http://www.who.int/about/en/

Read more information about this source


CATEGORY 3 RESTRICTIONS APPLY
Contact: Office of Publications, World Health Organization; 1211 Geneva 27; Switzerland;

Read more information about this source

ICD10AM_2000 - National Centre for Classification in Health, University of Sydney, Faculty of Health Sciences; International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification; 2nd Edition; January 2000;

CATEGORY 3 RESTRICTIONS APPLY
Contact: National Centre for Classification in Health, University of Sydney, Faculty of Health Sciences; PO Box 170; Lidcombe; NSW; Australia; 1825; +61 2 9351 9461; D.Truran@cchs.usyd.edu.au

Read more information about this source

ICD10AMAE_2000 - International Statistical Classification of Diseases and Related Health Problems, Australian Modification (ICD-10-AM), Americanized English Equivalents; Bethesda (MD); National Library of Medicine; 2000;

CATEGORY 3 RESTRICTIONS APPLY
Contact: National Centre for Classification in Health University of Sydney Faculty of Health Sciences; PO Box 170; Lidcombe; NSW; Australia; 1825; +61 2 9351 9461;

Read more information about this source
ICF_2008_12_19 - World Health Organization; International Classification of Functioning, Disability and Health; Geneva, Switzerland; World Health Organization; 2008; 12/19/2008; http://www.who.int/classification/icf;

CATEGORY 4 RESTRICTIONS APPLY to U.S. UMLS USERS

CATEGORY 3 RESTRICTIONS APPLY to Non-U.S. UMLS USERS

Contact: Nenad Kostanjsek; Technical Officer, Classification, Terminology and Standards (CTS), Department of Health Statistics and Informatics (HSI); World Health Organization; 20, Avenue Appia; CH-1211 Geneva 27; Switzerland; +41.22.791.3242; +41.22.791.4894; kostanjsekn@who.int; http://www.who.int/classification/icf;

ICF-CY_2008 - World Health Organization; International Classification of Functioning, Disability and Health for Children and Youth; Geneva, Switzerland; World Health Organization; 2008; http://www.who.int/classification/icf;

CATEGORY 4 RESTRICTIONS APPLY to U.S. UMLS USERS

CATEGORY 3 RESTRICTIONS APPLY to Non-U.S. UMLS USERS

Contact: Nenad Kostanjsek; Technical Officer, Classification, Terminology and Standards (CTS), Department of Health Statistics and Informatics (HSI); World Health Organization; 20, Avenue Appia; CH-1211 Geneva 27; Switzerland; +41.22.791.3242; +41.22.791.4894; kostanjsekn@who.int; http://www.who.int/classification/icf;

ICNP_2019 - International Council of Nurses; International Classification for Nursing Practice (ICNP); Geneva, Switzerland; International Council of Nurses; 2019;

CATEGORY 3 RESTRICTIONS APPLY

Contact: Amy Amherdt; Administrative Assistant, eHealth Programme, International Council of Nurses; International Classification for Nursing Practice (ICNP) Programme; University of Wisconsin - Milwaukee, College of Nursing; Milwaukee, WI; United States; 53201; (414) 229-5146; aamherdt@uwm.edu; https://www.icn.ch/what-we-do/projects/ehealth-icnp;

ICNP_2017 - International Classification for Nursing Practice (ICNP); Geneva, Switzerland; International Council of Nurses; 2017;

CATEGORY 3 RESTRICTIONS APPLY

Contact: Amy Coenen; Director, International Classification for Nursing Practice (ICNP) Programme; University of Wisconsin - Milwaukee, College of Nursing; Milwaukee, WI; United States; 53201; (414) 229-5146; coenena@uwm.edu; https://www.icn.ch/what-we-do/projects/ehealth-icnp;

ICPC93 - The International Classification of Primary Care (ICPC); Denmark; World Organisation of Family Doctors; 1993;
This year, the Metathesaurus has also included translations of ICPC93 in the following languages:

- Basque (ICPCBAQ_1993),
- Danish (ICPCDAN_1993),
- Dutch (ICPCDUT_1993),
- Finnish (ICPCFIN_1993),
- French (ICPCFRE_1993),
- German (ICPCGER_1993),
- Hebrew (ICPCHEB_1993),
- Hungarian (ICPCHUN_1993),
- Italian (ICPCITA_1993),
- Norwegian (ICPCNOR_1993),
- Portuguese (ICPCPOR_1993),
- Spanish (ICPCSPA_1993), and
- Swedish (ICPCSWE_1993).

Contact: UMLS Support;;National Library of Medicine;;;;;;;;;custserv@nlm.nih.gov;

Read more information about this source

---

**ICPC2EDUT_200203** - Hirs, W., H.W. Becker, C. van Boven, S.K. Oskam, I.M. Okkes, H. Lamberts.; International Classification of Primary Care 2E: 2nd ed. electronic. Dutch Translation.; 2nd ed.; Amsterdam; Department of General Practice, Academic Medical Center/University of Amsterdam, Dutch College of General Practitioners (NHG); March 2002.;

**CATEGORY 3 RESTRICTIONS APPLY**

Contact: UMLS Support;;National Library of Medicine;;;;;;;;;custserv@nlm.nih.gov;

Read more information about this source

---

**ICPC2EEENG_200203** - Classification Committee of the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians (WONCA), known more briefly as the World Organization of Family Doctors; Henk Lamberts and Inge Hofmans-Okkes; International Classification of Primary Care; 2nd ed.; World Organization of Family Doctors; 2002.;

**CATEGORY 3 RESTRICTIONS APPLY**

Contact: UMLS Support;;National Library of Medicine;;;;;;;;;custserv@nlm.nih.gov;

Read more information about this source

---

**ICPC2ICD10DUT_200412** - Classification Committee of the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians (WONCA), known more briefly as the World Organization of Family Doctors; Henk Lamberts and Inge Hofmans-Okkes; International Classification of Primary Care, Dutch Translation; 2nd ed.; World Organization of Family Doctors; 2002.;

**CATEGORY 3 RESTRICTIONS APPLY**

Contact: UMLS Support;;National Library of Medicine;;;;;;;;;custserv@nlm.nih.gov;

Read more information about this source

---

**ICPC2ICD10ENG_200412** - Classification Committee of the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians (WONCA), known more briefly as the World Organization of Family Doctors; Henk Lamberts and Inge Hofmans-Okkes; International Classification of Primary Care; 2nd ed.; World
ICPC2P_2005 - The International Classification of Primary Care (ICPC). Sydney; Family Medicine Research Centre, University of Sydney; December 2005.

ICPCBAQ_1993 - The International Classification of Primary Care (ICPC). Basque Translation.

ICPCDAN_1993 - The International Classification of Primary Care (ICPC). Danish Translation.

ICPCDUT_1993 - The International Classification of Primary Care (ICPC). Dutch Translation.

ICPCFIN_1993 - The International Classification of Primary Care (ICPC). Finnish Translation.

ICPCFRE_1993 - The International Classification of Primary Care (ICPC). French Translation.

Contact: UMLS Support; National Library of Medicine; custserv@nlm.nih.gov;
JABL99 - Online Congenital Multiple Anomaly/Mental Retardation Syndromes

CATEGORY 1 RESTRICTIONS APPLY

Contact: UMLS Support; National Library of Medicine; custserv@nlm.nih.gov

Read more information about this source

KCD5_2008 - Korean Standard Classification of Disease Version 5

CATEGORY 3 RESTRICTIONS APPLY

Contact: Bo-Young Jung; Korea Centers for Disease Control and Prevention; +82-2-3481-6791; +82-2-532-3820; happiness630@hanmail.net

Read more information about this source

LCH90 - Library of Congress Subject Headings

There are later editions of this source that are not reflected in the UMLS Metathesaurus. This source has considerable non-biomedical content and will never be included in the Metathesaurus in its entirety.

Contact: http://www.lcweb.loc.gov

Read more information about this source

LCH_NW_2013 - Northwestern University Library; Library of Congress Subject Headings, Northwestern University subset

Contact: Gary L. Strawn; Authorities Librarian; Northwestern University Library; 1970 Campus Drive; Evanston, IL; United States; 60208-2300; (847) 491-2788; (847) 491-8306; mrsmith@northwestern.edu; https://galter.northwestern.edu/About%20us/northwestern-university-libraries-lcsh-mesh-mapping-project;

Read more information about this source

LNC269 (updated) - The Regenstrief Institute, Inc.; Logical Observation Identifier Names and Codes (LOINC); Version 2.69; Indianapolis (IN); December 15, 2020

The following special notice must be displayed:

"This product includes all, or a portion of, or is derived from content from LOINC that is subject to a license from Regenstrief Institute, Inc. Your use of LOINC content also is subject to this license, a copy of which is available https://loinc.org/license/. The current complete LOINC distribution is available for download at http://loinc.org. The LOINC Table and LOINC codes are copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. The LOINC Table, LOINC Table Core, LOINC Panels and Forms File, LOINC Answer File, LOINC Part File, LOINC Group File, LOINC Document Ontology File, LOINC Hierarchies, LOINC Linguistic Variants File, LOINC/RSNA Radiology Playbook, LOINC/IEEE Medical Device Code Mapping Table, LOINC Display Name File, LOINC Consumer Name File, and LOINC Change Snapshot File are copyright © 1995-2020, Regenstrief Institute, Inc. All rights reserved. THE LOINC TABLE (IN ALL FORMATS), LOINC TABLE CORE, LOINC PANELS AND FORMS FILE, LOINC ANSWER"
The LOINC/IEEE Medical Device Code Mapping Table contains content from IEEE (http://ieee.org), copyright © 2019 IEEE.

This product includes all or a portion of the UCUM table, UCUM codes, and UCUM definitions or is derived from it, subject to a license from Regenstrief Institute, Inc. and The UCUM Organization. Your use of the UCUM table, UCUM codes, UCUM definitions also is subject to this license, a copy of which is available at http://unitsofmeasure.org. The current complete UCUM table, UCUM Specification are available for download at http://unitsofmeasure.org. The UCUM table and UCUM codes are copyright © 1995-2020, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. THE UCUM TABLE (IN ALL FORMATS), UCUM DEFINITIONS, AND SPECIFICATION ARE PROVIDED "AS IS." ANY EXPRESS OR IMPLIED WARRANTIES ARE DISCLAIMED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

Contact: LOINC c/o Regenstrief Institute;;The Regenstrief Institute, Inc;1101 West 10th Street;;Indianapolis;IN;United States;46202;(317) 274-9000;;loinc@loinc.org;https://loinc.org/;

Read more information about this source

LNC-DE-AT_269 (updated) - ;;The Regenstrief Institute, Inc.;Logical Observation Identifier Names and Codes (LOINC), German, Austria Edition;;Version 2.69;Austria;ELGA;December 15, 2020;;;;German;;

Contact: LOINC c/o Regenstrief Institute;;The Regenstrief Institute, Inc;1101 West 10th Street, Indianapolis, IN 46202;;Indianapolis;IN;United States;46202;(317) 274-9000;;loinc@loinc.org;https://loinc.org/;

Read more information about this source

LNC-DE-DE_269 (updated) - ;;The Regenstrief Institute, Inc.;Logical Observation Identifier Names and Codes (LOINC), German, Germany Edition;;Version 2.69;Germany;Institute for Medical Documentation and Information (DIMDI);December 15, 2020;;;;German;;

Contact: LOINC c/o Regenstrief Institute;;The Regenstrief Institute, Inc;1101 West 10th Street, Indianapolis, IN 46202;;Indianapolis;IN;United States;46202;(317) 274-9000;;loinc@loinc.org;https://loinc.org/;

Read more information about this source

LNC-EL-GR_269 (updated) - ;;The Regenstrief Institute, Inc.;Logical Observation Identifier Names and Codes (LOINC), Greek, Greece Edition;;Version 2.69;Greece;Efstratia Kontaxi, MD, MSc, and Evripidis Stefanidis, MD, with technical support from Panagiotis Kontaxis, Diploma of Electrical and Computer Engineering.;December 15, 2020;;;;Greek;;

Contact: LOINC c/o Regenstrief Institute;;The Regenstrief Institute, Inc;1101 West 10th Street, Indianapolis, IN 46202;;Indianapolis;IN;United States;46202;(317) 274-9000;;loinc@loinc.org;https://loinc.org/;

Read more information about this source

LNC-ES-AR_269 (updated) - ;;The Regenstrief Institute, Inc.;Logical Observation Identifier Names and Codes (LOINC), Spanish, Argentina Edition;;Version 2.69;Argentina;Conceptum Medical Terminology Center;December 15, 2020;;;;Spanish;;

Contact: LOINC c/o Regenstrief Institute;;The Regenstrief Institute, Inc;1101 West 10th Street, Indianapolis, IN 46202;;Indianapolis;IN;United States;46202;(317) 274-9000;;loinc@loinc.org;https://loinc.org/;

Read more information about this source
MDR23_1 (updated) - Medical Dictionary for Regulatory Activities Terminology (MedDRA); Version 23.1; MedDRA MSSO; September 2020;

CATEGORY 3 RESTRICTIONS APPLY

Contact: MedDRA MSSO; 7575 Colshire Drive; McLean; VA; United States; 22102; 1-877-258-8280 (Toll free international, 1-703-556-2950 (Direct); 1-703-556-1744; mssohelp@meddra.org; https://www.meddra.org/

Read more information about this source

MDRBPO23_1 (updated) - Medical Dictionary for Regulatory Activities Terminology (MedDRA), Brazilian Portuguese Edition; Version 23.1; MedDRA MSSO; September 2020;

CATEGORY 3 RESTRICTIONS APPLY

Contact: MedDRA MSSO; 7575 Colshire Drive; McLean; Virginia; United States; 22102; 1-877-258-8280 (Toll free international, 1-703-556-2950 (Direct); 1-703-556-1744; mssohelp@meddra.org; https://www.meddra.org/

Read more information about this source

MDRCZE23_1 (updated) - Medical Dictionary for Regulatory Activities Terminology (MedDRA), Czech Edition; Version 23.1; MedDRA MSSO; September 2020;

CATEGORY 3 RESTRICTIONS APPLY

Contact: MedDRA MSSO; 7575 Colshire Drive; McLean; Virginia; United States; 22102; 1-877-258-8280 (Toll free international, 1-703-556-2950 (Direct); 1-703-556-1744; mssohelp@meddra.org; https://www.meddra.org/

Read more information about this source

MDRDUT23_1 (updated) - Medical Dictionary for Regulatory Activities Terminology (MedDRA), Dutch Edition; Version 23.1; MedDRA MSSO; September 2020;

CATEGORY 3 RESTRICTIONS APPLY

Contact: MedDRA MSSO; 7575 Colshire Drive; McLean; Virginia; United States; 22102; 1-877-258-8280 (Toll free international, 1-703-556-2950 (Direct); 1-703-556-1744; mssohelp@meddra.org; https://www.meddra.org/

Read more information about this source

MDRFRE23_1 (updated) - Medical Dictionary for Regulatory Activities Terminology (MedDRA), French Edition; Version 23.1; MedDRA MSSO; September 2020;

CATEGORY 3 RESTRICTIONS APPLY

Contact: MedDRA MSSO; 7575 Colshire Drive; McLean; Virginia; United States; 22102; 1-877-258-8280 (Toll free international, 1-703-556-2950 (Direct); 1-703-556-1744; mssohelp@meddra.org; https://www.meddra.org/

Read more information about this source
NCI2020_CBDD_2009D (updated) - Chemical Biology and Drug Development Vocabulary; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_CDC_2009D (updated) - U.S. Centers for Disease Control and Prevention, Department of Health and Human Services; October 9, 2020; Atlanta, GA;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_CDISC_2009D (updated) - Clinical Data Interchange Standards Consortium; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_CDISC-GLOSS_2009D (updated) - CDISC Glossary Terminology; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_CELLOSARUS_2009D (updated) - Cellosaurus; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_CRCH_2009D (updated) - Cancer Research Center of Hawaii, University of Hawaii; Cancer Research Center of Hawaii Nutrition Terminology; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_CTCAE_2009D (updated) - Common Terminology Criteria for Adverse Events; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;
NCI2020_ICH_2009D (updated) - International Conference on Harmonization; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_INC_2009D (updated) - International Neonatal Consortium Terms; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_JAX_2009D (updated) - Jackson Laboratories; Jackson Laboratories Mouse Terminology, adapted for NCI use; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_KEGG_2009D (updated) - Kyoto Encyclopedia of Genes and Genomes (KEGG), KEGG Pathway Database, adapted for NCI use; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_NCI-GLOSS_2009D (updated) - NCI Dictionary of Cancer Terms; Bethesda, MD; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_NCI-HGNC_2009D (updated) - NCI HUGO Gene Nomenclature; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

NCI2020_NCI-HL7_2009D (updated) - Health Level 7; October 9, 2020;
Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;
Read more information about this source

NCI2020_NCPDP_2009D (updated) - National Council for Prescription Drug Programs; 20.09d; Scottsdale, AZ; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

Read more information about this source

NCI2020_NICHD_2009D (updated) - National Institute of Child Health and Human Development, National Institutes of Health; 20.09d; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

Read more information about this source

NCI2020_PCDC_2009D (new) - Pediatric Cancer Data Commons; 20.09d; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

Read more information about this source


Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

Read more information about this source

NCI2020_PI-RADS_2009D (updated) - Prostate Imaging Reporting and Data System; 20.09d; October 9, 2020; http://www.acr.org/Quality-Safety/Resources/PIRADS;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

Read more information about this source

NCI2020_RENI_2009D (updated) - Registry Nomenclature Information System; 20.09d; October 9, 2020;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;

Read more information about this source

NCI2020_UCUM_2009D (updated) - Schadow, Gunther and McDonald, Clement; Regenstrief Institute, Inc. and The UCUM Organization; Unified Code for Units of Measure; 20.09d; October 9, 2020, Indianapolis, IN;

Contact: Enterprise Vocabulary Services (EVS); National Cancer Institute; 240-276-5541, 1-888-478-4423 (toll free); ncicbiit@mail.nih.gov; https://cbiit.cancer.gov/application-support;
NUCC_HCPT_20.1 (new) - National Uniform Claim Committee; National Uniform Claim Committee - Health Care Provider Taxonomy; American Medical Association; July 1, 2020; Chicago, IL; 

OMIC2021_02_08 (updated) - McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD); Online Mendelian Inheritance in Man (OMIM); Baltimore, MD; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University; February 8, 2021; 

OMS2005 - Martin, Karen S.; The Omaha System: A Key to Practice, Documentation, and Information Management; 2nd; Omaha, NE; Health Connections Press; 2005; 

PCDS97 - Ozbolt, Judy Grace; Patient Data Care Set (PCDS); Version 4.0; Nashville, TN; 1998; 

PDQ_2018_10_27 - Physician Data Query; National Cancer Institute; October 27, 2018; 

PNDS_4_2018 - AORN; Carol Petersen; Perioperative Nursing Data Set, 4th edition, 2018; 3rd edition; Denver, CO; AORN;
PPAC98 - Pharmacy Practice Activity Classification (PPAC); Version 1; Washington (DC); American Pharmaceutical Association; 1998.


QMR96 - Quick Medical Reference (QMR); San Bruno (CA); First DataBank; 1997.

RAM99 - Dr. Randolph A. Miller; QMR clinically related terms; 1999.

RCD99 - Clinical Terms Version 3 (CTV3) (Read Codes) (Q199); National Health Service National Coding and Classification Centre; March, 1999.

RCDAE_1999 - American English equivalent of the Clinical Terms; Version 3 (Q1, 1999); Bethesda (MD); National
Library of Medicine, UMLS project;1999;;;;;;;

CATEGORY 3 RESTRICTIONS APPLY

Contact: ;;;;;;;;

Read more information about this source

RCDSA_1999 - ;;;;American English equivalent of synthesized terms from the Clinical Terms ;;;Version 3 (Q1, 1999);Bethesda (MD);National Library of Medicine, UMLS project;1999;;;;;;;

CATEGORY 3 RESTRICTIONS APPLY

Contact: ;;NHS Information Authority Loughborough;Woodgate;;Loughborough;Leicestershire ;;LE11 2TG;;+44 (0) 1509 211611;helpdesk3@nhsccc.exec.nhs.uk;

Read more information about this source

RCDSY_1999 - ;;;;Synthesized Read terms (without initial bracketed letters) of the Clinical Terms;;;Version 3 (Q1, 1999);Bethesda (MD);National Library of Medicine, UMLS project;1999;;;;;;;

CATEGORY 3 RESTRICTIONS APPLY

Contact: ;;NHS Information Authority Loughborough;Woodgate;;Loughborough;Leicestershire ;;LE11 2TG;;+44 (0) 1509 211611;helpdesk3@nhsccc.exec.nhs.uk;

Read more information about this source

RXNORM_20AA_210301F (updated) - ;;;;RxNorm;;;META2020AA Full Update 2021_03_01;Bethesda, MD;National Library of Medicine;;;;;;;

This release contains concepts created by the National Library of Medicine which express the meaning of a drug name in a normalized form. These concepts relate the names of orderable medications to a dose form and the components of those medications. For further discussion, see the article at:


Contact: RxNorm Customer Service;;U.S. National Library of Medicine;8600 Rockville Pike;;Bethesda, MD;United States;20894;(888) FIND-NLM;;rxnorminfo@nlm.nih.gov;https://www.nlm.nih.gov/research/umls/rxnorm/

Read more information about this source

SCTSPA_2020_10_31 (updated) - ;;SNOMED International;;;SNOMED CT Spanish Edition;;;Spanish Language Edition;London, United Kingdom;;;October 31, 2020;;;;;

TERMS IN APPENDIX 2 OF UMLS LICENSE APPLY.

TERMS IN APPENDIX 2 OF UMLS LICENSE APPLY.

"This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT®, was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO."

Contact: UMLS Support, National Library of Medicine; e-mail: NLM_SNOMED_CT_Support

TERMS IN APPENDIX 2 OF UMLS LICENSE APPLY.

TERMS IN APPENDIX 2 OF UMLS LICENSE APPLY.

"This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT®, was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO."

Contact: UMLS Support, National Library of Medicine; e-mail: NLM SNOMED CT Support

NLM is a Charter Member of the IHTSDO on behalf of the U.S.

Contact: NLM Customer service;NLM is a Charter Member of SNOMED International on behalf of the U.S.;National Library of Medicine;8600 Rockville Pike;;Bethesda;MD;United States;20894;1-888-FIND-NLM (1-888-346-3656);https://support.nlm.nih.gov/support/create-case/;;

Read more information about this source

SNOMEDCT_US_2018_03_01 - ;;SNOMED International;;US Edition of SNOMED CT;;;;London, United Kingdom;SNOMED International;;;;March 1, 2018;;;;;

TERMS IN APPENDIX 2 OF UMLS LICENSE APPLY.

TERMS IN APPENDIX 2 OF UMLS LICENSE APPLY.

"This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT®, was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO."

Contact: UMLS Support, National Library of Medicine; e-mail: NLM SNOMED CT Support

NLM is a Charter Member of the IHTSDO on behalf of the U.S.

Contact: NLM Customer service;NLM is a Charter Member of the IHTSDO on behalf of the U.S.;National Library of Medicine;8600 Rockville Pike;;Bethesda;MD;United States;20894;1-888-FIND-NLM (1-888-346-3656);custserv@nlm.nih.gov;;

Read more information about this source

SRC - UMLS Metathesaurus Source Terminologies; Bethesda, MD; National Library of Medicine;
Contact: UMLS Support; custserv@nlm.nih.gov
Read more information about this source

TKMT2011 - Traditional Korean Medical Terms; 2011; Korea; KOR;
Contact: Jinhyun Kim; Researcher/O.M.D; Information Research Center, TKM Information Research Division, Korea Institute of Oriental Medicine; 483 Expo-ro, Yuseong-gu; Daejeon; Korea; 305-811; +82-42-868-9565, +82-10-2237-2378; +82-42-861-9421; kjh970203@kiom.re.kr
Read more information about this source

ULT93 - Ultrasound Structured Attribute Reporting (UltraSTAR); Boston (MA); Brigham & Womens Hospital; 1993;
CATEGORY 3 RESTRICTIONS APPLY
Contact: Robert Greenes, M.D., Ph.D.; Brigham & Womens Hospital; Department of Radiology; 75 Francis Street; Boston; MA; 02115; (617) 732-6281; greenes@harvard.edu
Read more information about this source

UMD2021 (updated) - ECRI Institute; Universal Medical Device Nomenclature System; 2021; Plymouth Meeting, PA;
CATEGORY 1 RESTRICTIONS APPLY
Contact: Elizabeth Richardson; Director of Database and Nomenclature Systems; ECRI; 5200 Butler Pike; Plymouth Meeting; Pennsylvania; United States; 19462-1298; 1-610-825-6000 ext. 5891; 1-610-834-1275; umdns@ecri.org; https://www.ecri.org/components/UMDNS/Pages/default.aspx
Read more information about this source

USP_2021_02_15 (updated) - USP Compendial Nomenclature; February, 2021; United States Pharmacopeia; February, 2021;
Contact: Steven Emrick; Senior HIT Product Manager; United States Pharmacopeia; 12601 Twinbrook Parkway; Rockville; MD; US; 20852-1790; 1-800-227-8772; HealthcareQuality@usp.org; http://www.usp.org/health-quality-safety
Read more information about this source

USPMG_2020 - USP Medicare Model Guidelines; Version 8; United States Pharmacopeia; February 1, 2020;
Contact: Jami S. Earnest, PharmD; Senior Scientific Liaison; United States Pharmacopeia; 12601 Twinbrook Parkway; Rockville; MD; US; 20852-1790; 1-800-227-8772; ModelGuidelines@usp.org; https://www.usp.org/health-quality-safety/usp-medicare-model-guidelines
Read more information about this source

UWDA173 - University of Washington Digital Anatomist, (UWDA); Version 1.7.3; Seattle (WA); University of Washington; March, 2003;
Contact: Jose Mejino, M.D.; University of Washington Digital Anatomist Symbolic Knowledge Base, University of Washington Digital Anatomist Information System, Structural Informatics Group; Department of Biological Structure; Seattle; WA; 98195; onard@biostr.washington.edu

Read more information about this source

**VANDF_2021_01_29** (updated) - Veterans Health Administration National Drug File; January 29, 2021; Washington, DC; U.S. Department of Veterans Affairs; 

*NOTE:* Now a CATEGORY 0.

Contact: Michael Lincoln, M.D.; U.S. Department of Veterans Affairs, Veterans Health Administration; Washington; DC; United States; michael.lincoln@med.va.gov; http://www.pbm.va.gov/default.aspx

Read more information about this source

**WHO97** - WHO Adverse Drug Reaction Terminology (WHOART); Uppsala (Sweden); WHO Collaborating Centre for International Drug Monitoring; 1997; 

**CATEGORY 2 RESTRICTIONS APPLY**

The Metathesaurus includes translations of WHO97 in:

- French (WHOFRE_1997),
- German (WHOGER_1997),
- Portuguese (WHOPOR_1997), and
- Spanish (WHOSPA_1997).

Contact: WHO Collaborating Centre for International Drug Monitoring; Stora Target 3; S-753 20; Uppsala; Sweden; +46-18-656080;

Read more information about this source

**WHOFRE_1997** - WHO Adverse Drug Reaction Terminology (WHOART). French Translation; Uppsala (Sweden); WHO Collaborating Centre for International Drug Monitoring; 1997; 

**CATEGORY 2 RESTRICTIONS APPLY**

Contact: WHO Collaborating Centre for International Drug Monitoring; Stora Target 3; S-753 20; Uppsala; Sweden; +46-18-656080;

Read more information about this source

**WHOGER_1997** - WHO Adverse Drug Reaction Terminology (WHOART). German Translation; Uppsala (Sweden); WHO Collaborating Centre for International Drug Monitoring; 1997; 

**CATEGORY 2 RESTRICTIONS APPLY**

Contact: WHO Collaborating Centre for International Drug Monitoring; Stora Target 3; S-753 20; Uppsala; Sweden; +46-18-656080;

Read more information about this source

**WHOPOR_1997** - WHO Adverse Drug Reaction Terminology (WHOART). Portuguese Translation; Uppsala
APPENDIX 2

SNOMED CT® AFFILIATE LICENSE AGREEMENT

IMPORTANT NOTICE – PLEASE READ THE FOLLOWING CAREFULLY

This is a License Agreement between (1) The International Health Terminology Standards Development Organisation, a private company limited by guarantee and established under the laws of England (registered number 09915820), with its registered office at One Kingdom Street, Paddington Central, London, W2 6BD (the "Licensor"), and (2) the person or organization to which the International Release of SNOMED CT (whether on its own or as part of a Member's National Release of SNOMED CT) is distributed or otherwise made available (the "Licensee").

By downloading, accessing or using any part of the International Release of SNOMED CT or a Member's National Release of SNOMED CT, or exercising any rights granted under this License Agreement, the Licensee agrees to be bound by the terms of this License Agreement.

License Fees and other conditions and restrictions apply to the use of the International Release of SNOMED CT in a Non-Member Territory, and to the deployment, distribution and licensing of Licensee Products within a Non-Member Territory. In this regard the Licensee's attention is drawn in particular to clause 7 (License Fees) and clause 9 (Use in Member Territories and Non-Member Territories).

1. DEFINED TERMS

In this License Agreement, terms defined in Appendix A (Defined Terms) have the meanings set out in that Appendix.

2. GRANT OF LICENSE

The Licensor grants the Licensee, subject to the terms of this License Agreement, a perpetual (subject to revocation in accordance with clause 5), worldwide, non-exclusive, non-transferable license for the term of this License Agreement to:

2.1.1 use, and permit the Licensee's officers, employees, agents and contractors to use, the International Release;

2.1.2 create Extensions and Derivatives from the International Release and use and modify those Extensions and Derivatives;

2.1.3 incorporate the International Release into Licensee Products, and distribute Licensee Products under a sub-license in accordance with clause 2.1.5;

2.1.4 modify the manner of formatting of the copy of the SNOMED CT Core distributed to the Licensee as part of the International Release or as part of a Member's National Release; and

2.1.5 subject to clause 5.8, grant sub-licenses of the International Release to End Users to the extent necessary for the End Users to use the Licensee Products.
2.2 The Licensee may only use the International Release, and must ensure that its officers, employees, agents and contractors only use the International Release:

2.2.1 for the Licensee's internal business purposes (including the creation by the Licensee of Extensions, Derivatives and other Licensee Products along with the licensing and distribution by the Licensee of the Licensee Products);

2.2.2 in the development and operation of the Licensee's information systems;

2.2.3 for the Licensee's research purposes; and/or

2.2.4 in the Licensee's systems (including browsers and data analysis systems) made available to the general public for accessing and/or retrieving any part of the International Release and/or data encoded using the foregoing, provided that users of those systems are not able to extract any substantial portion of SNOMED CT and provided further that no fee is charged for access to those systems except where access is incidental to the provision of training or consulting services.

2.3 The Licensee is only permitted under this License Agreement to create Extensions from the International Release and to create Derivatives from the International Release and from those Extensions. The Licensee may only create an Extension or a Derivative from any Member's Extension pursuant to a license agreement with that Member in respect of the Member's National Release.

2.4 The Licensee is not permitted to translate any part of the International Release into any other human language without the prior written consent of the Licensor.

2.5 Each sub-license granted by the Licensee under clause 2.1.5 must:

2.5.1 not grant the End User any greater rights in respect of the International Release than the Licensee itself has under this License Agreement;

2.5.2 not permit the End User to do any act or thing in respect of the International Release that the Licensee is prohibited from doing under this License Agreement;

2.5.3 not permit the End User to sub-license or transfer any of its rights under the sub-license (unless the End User is also an Affiliate, in which case that Affiliate shall be entitled to sub-license further its rights under the sub-license with the Licensee, subject to the same restrictions as apply to sub-licensing the International Release under the Affiliate's license agreement with the Licensor);

2.5.4 terminate automatically upon termination of this License Agreement;

2.5.5 provide that the End User may apply directly to the Licensor upon receiving notice that the sub-license will terminate in accordance with clause 2.5.4, and that the Licensor may in such circumstances (but shall not be obliged to):

   (a) grant the End User a license in respect of the International Release for a limited period in order to enable the End User to continue to use the Licensee Products that are subject to the sub-license during that period; or

   (b) give the End User an assurance or undertaking that for a limited period the Licensor will not seek to prevent the End User from using the Licensee Products; and

2.5.6 permit the Licensee to disclose the terms of the sub-license to the Licensor in accordance with clauses 7 and 8.

2.6 If the Licensee becomes aware of any material error or change or correction needed in the International Release, the
Licensee agrees to advise the Licensor promptly of such error, change or correction by following the Licensor's procedures for change notification that the Licensor prescribes by Regulations and notifies to the Licensee from time to time.

2.7 The Licensee shall comply with the Internet security measures that the Licensor prescribes by Regulations and notifies to the Licensee from time to time.

3. EXTENSIONS AND DERIVATIVES

3.1 The Licensee may not create any Standards-Based Extension or any Standards Based Derivative unless it has first been issued with a Namespace Identifier by or on behalf of the Licensor.

3.2 The Licensee may request that the Licensor issue it with a Namespace Identifier, and the Licensor shall not unreasonably refuse to do so taking into account amongst other things quality assurance, governance processes, Standards and Regulations.

3.3 The Licensee shall ensure that all Standards-Based Extensions and Standards Based Derivatives that the Licensee creates under this License Agreement are created in accordance with, and comply with, all applicable Standards (including, without limitation, as to the use of Namespace Identifiers).

3.4 Subject to clauses 3.5 and 3.6, the Licensee shall own all Intellectual Property Rights in all Extensions and Derivatives that the Licensee creates under this License Agreement. The Licensee may not assign or otherwise transfer those Intellectual Property Rights to any other person unless (i) that person is an Affiliate and, in the case of Standards-Based Extensions or Standards-Based Derivatives, has a Namespace Identifier; and (ii) the transfer is notified in writing to the Licensor within thirty (30) days after the transfer.

3.5 The Licensee shall, if requested by the Licensor, transfer to the Licensor or a Member nominated by the Licensor all of its Intellectual Property Rights in such Standards-Based Extensions (or parts thereof) as the Licensor may specify.

3.6 The Licensee shall, if requested by the Licensor and agreed by the Licensee in the Licensee's sole discretion, transfer to the Licensor or a Member nominated by the Licensor all of its Intellectual Property Rights in such Standards-Based Derivatives as the Licensor may specify.

3.7 Upon the transfer to the Licensor, or to a Member, of the Intellectual Property Rights in any Standards-Based Extension (or part thereof) or Standards-Based Derivative in accordance with clauses 3.5 or 3.6:

   3.7.1 responsibility for the maintenance and distribution of that Extension (or part thereof) or Derivative shall also transfer from the Licensee to the Licensor or the Member (as the case may be); and

   3.7.2 the Licensor hereby grants a license back to the Licensee from the Licensor or will procure from the Member a license back to the Licensee (as the case may be) of that Extension (or part thereof) or Derivative, on the same terms as apply to the International Release under clause 2 of this License Agreement, until that Extension (or part thereof) or Derivative becomes part of the International Release or the Member's National Release (as the case may be).

4. MODIFICATIONS TO THE INTERNATIONAL RELEASE

4.1 Subject to clause 2.1.4, the Licensee may not modify any part of the SNOMED CT Core distributed as part of the International Release or as part of a Member's National Release.

4.2 Subject to any express and specific statement to the contrary in the documentation distributed as part of the International Release, the Licensee may not modify any of the documentation (including Specifications) or software (unless provided in source code form) distributed as part of the International Release.

4.3 The Licensee may, by written notice, request the Licensor to modify the SNOMED CT Core. Upon receipt of such
written notice, the Licensor shall consult with the Licensee and shall give due consideration as to whether the proposed modification should be made based on the Licensor's editorial guidelines and policies. Following due consideration of the matter, including consideration of any information presented by the Licensee, the Licensor shall inform the Licensee whether the proposed modification shall be made and if the Licensor agrees that the proposed modification should be made, the Licensor shall give a non-binding indication of when, reasonably and in good faith, it anticipates that the proposed modification will be made. If the Licensee would like the content of the proposed modification to be developed more quickly than the Licensor has indicated, the Licensee may itself undertake or procure the undertaking of the development of the content of the proposed modification (outside of any existing Licensor's support services contract). On receipt of the developed content of the proposed modification, the Licensor will then give due consideration as to whether the developed content meets the Licensor's quality assurance, other governance processes, Standards and Regulations. If the developed content meets the Licensor's quality assurance, other governance processes, Standards and Regulations then the Licensor shall incorporate the modification into the SNOMED CT Core according to its schedule which will give due consideration as to when the proposed modification shall be incorporated into the SNOMED CT Core, taking into account other proposals for the modification of the SNOMED CT Core and the work required to include the proposed modification in the SNOMED CT Core.

5. TERM AND TERMINATION

5.1 This License Agreement shall commence on the date on which it comes into effect in accordance with the notice at the beginning of this License Agreement, and shall continue until terminated in accordance with this clause 5.

5.2 Either party may terminate this License Agreement if the other party commits a material breach of any of its obligations under this License Agreement (which, in the case of the Licensee, shall include, without limitation, any failure to pay License Fees when due under clause 7) in accordance with the following procedure:

5.2.1 the party seeking to terminate the License Agreement (the "Terminating Party") shall serve an escalation notice (the "Escalation Notice") on the other party (the "Defaulting Party") requiring the Defaulting Party to nominate a member of its senior management team to meet with a member of the Terminating Party's senior management team to seek to resolve in good faith the matter giving rise to the service of the escalation notice.

5.2.2 The representatives of the parties identified in accordance with clause 5.2.1 shall meet in good faith to seek to resolve the matter. If they are unable to resolve the matter within 45 days of the date of the Escalation Notice the Terminating Party may serve a formal breach notice (the "Breach Notice") on the Defaulting Party requiring it to remedy the breach within 90 days.

5.2.3 If the Defaulting Party does not remedy the breach within 90 days of the date of the Breach Notice the Terminating Party may terminate the License Agreement by giving 180 days' written notice to the Defaulting Party (the "Termination Notice").

5.3 Neither party may terminate this License Agreement except in accordance with this clause 5.

5.4 The Licensee may terminate this License Agreement by giving up to twelve (12) months' prior written notice to the Licensor.

5.5 Upon termination of this License Agreement in accordance with this clause 5, all licenses granted under this License Agreement shall automatically and immediately be revoked.

5.6 The Licensee shall, by no later than forty five (45) days after termination of this License Agreement for any reason, remove all copies of the International Release from its computer systems and destroy all copies of electronic, paper copy and other media containing or representing any part of the International Release. The Licensee shall, if requested by the Licensor, certify in writing to the Licensor that the Licensee has complied with its obligations under this clause 5.6.

5.7 The Licensee shall, as soon as reasonably practicable following either party giving a Termination Notice for any reason, and in any event by no later than ninety (90) days after such Termination Notice is given, give written notice of
such termination to each End User that the Licensee reasonably believes to be a current user of a Licensee Product and to each Member in each Member Territory in which the Licensee has distributed or licensed any Licensee Product.

5.8 The Licensee may not grant any new sub-license under clause 2.1.5 after either party has given notice under clauses 5.2 or 5.4.

5.9 The Licensor shall be entitled to publicize the termination of this License Agreement to such persons (including Members, other Affiliates of the Licensor and End Users) and in such manner as it sees fit.

5.10 Clauses 5.6, 5.7, 5.8, 5.9, 5.11, 5.12, 7, 8 and 10 to 14 inclusive shall survive termination of this License Agreement.

5.11 The Licensee shall, by no later than thirty (30) days after termination of this License Agreement for any reason, submit a statement of account in accordance with clause 7.3 in respect of all periods that have not previously been covered by a statement of account under that clause.

5.12 Any termination of this License Agreement, for any reason, is without prejudice to the accrued liabilities of each party as at the date of termination (including, without limitation, any liability of the Licensee to pay License Fees that has accrued as at the date of termination), or to the Licensee's obligation to pay License Fees arising from the statement of account submitted under clause 5.11.

6. NEW VERSIONS AND CHANGES TO LICENSE TERMS

6.1 The Licensor shall notify the Licensee when each new version of the International Release is made available and there shall be a mechanism for the Licensee to access or obtain copies of the new version of the International Release. The Licensee shall be liable for any reasonable distribution charge, if applicable, established by the Licensor for each copy of the new version of the International Release.

6.2 Within one-hundred and eighty (180) days after the Licensor has notified the Licensee of the release of a new version of the International Release, the Licensee must upgrade the version of the International Release in its own systems and in the Licensee Products to that new version (or alternatively, if a subsequent version of the International Release is or has been released during the 180-day period, to that subsequent version at the Licensee's option).

6.3 The Licensor may vary the terms of this License Agreement by giving written notice to the Licensee. Any such variation shall take effect not less than ninety (90) days after the notice is given, as specified in the notice. If the Licensee does not wish this License Agreement to continue subject to the variation, the Licensee may terminate this License Agreement in accordance with clause 5.4, and if the Licensee gives notice of such termination before the variation takes effect then the variation shall not apply as between the Licensor and the Licensee.

6.4 The College of American Pathologists, as originator of Intellectual Property Rights in the International Release, shall as a licensee have a specific [exception] to the Licensor's rights in clause 6.3 in specific circumstances and for a specific fixed term period to be agreed with the Licensor, and the terms of such special [ exemption] shall be deemed part of such licensee's Affiliate License Terms. The Licensor will publish the terms of the special exemption with the Articles.

7. LICENSE FEES

7.1 The Licensee shall pay the License Fees to the Licensor in respect of the Licensee's activities in Non-Member Territories. The License Fees shall be payable annually in arrear.

7.2 All License Fees and other amounts payable to the Licensor under this License Agreement are exclusive of value added tax and any other tax of a similar nature, which shall be payable by the Licensee at the prevailing rate in addition to those amounts.

7.3 The Licensee shall, at least once in each calendar year, submit a statement of account to the Licensor in such manner
and form as the Licensor may prescribe from time to time, setting out the Licensee's activities in Non-Member Territories since the end of the period covered by the previous statement of account submitted under this clause 7.3 (or, in the case of the first statement of account under this clause 7.3, since the date on which this License Agreement became effective), and the Licensee's calculation of the License Fees and other amounts payable to the Licensor in respect of that period. Each such statement of account shall include, without limitation, a list of all license agreements in respect of Licensee Products that were in force during the period covered by the statement of account and, in relation to each such license agreement, the dates on which: (a) that license agreement was entered into or otherwise became effective; (b) the Licensee Product was first provided or made available to the licensee under that license agreement; and (c) the International Release (or any part of it) was first made available to the licensee under that license agreement.

7.4 The Licensee shall provide the Licensor with such information as the Licensor may reasonably request for the purpose of verifying any statement of account submitted to the Licensor under clause 7.3.

7.5 The Licensor shall, following receipt of a statement of account from the Licensee under clause 7.3, submit an invoice to the Licensee setting out the License Fees and other amounts payable by the Licensee in respect of the period to which the statement of account relates. The Licensee shall pay to the Licensor all amounts set out on each invoice submitted under this clause 7.5 within thirty (30) days of receipt of that invoice. The Licensee shall make payment under this clause 7.5 by wire transfer or by such other means as the Licensor may make available to the Licensee from time to time.

7.6 Interest shall accrue on any outstanding License Fees and other amounts at the rate of the lesser of (a) 500 basis points above the European Inter-Bank Offer Rate (EURIBOR), calculated daily from the date on which payment was due and compounding at the end of each calendar month or (b) the maximum amount allowed under applicable law.

8. PROTECTION OF THE LICENSOR'S INTELLECTUAL PROPERTY

8.1 Nothing in this License Agreement transfers to the Licensee any right, title or interest in or to the Intellectual Property Rights in the International Release or any part of it, or grants the Licensee any license in respect of the International Release or any part of it except as expressly set out in clause 2.

8.2 The Licensee shall not:

8.2.1 use any trademark or service mark (or any registrations thereof) other than the Licensor's trademarks, in any name that includes the word "SNOMED" or that is confusingly similar to SNOMED CT or any other similar trademark;

8.2.2 apply for any trade mark or service mark (or any registrations thereof) in any name that includes the word "SNOMED", or that is confusingly similar to SNOMED, SNOMED CT or any other similar trade mark;

8.2.3 abbreviate the marks SNOMED or SNOMED CT; or

8.2.4 do anything with respect to the foregoing trade marks that damages or could reasonably be deemed to reflect adversely on the Licensor or such trade marks.

8.3 The Licensee shall:

8.3.1 include the following notice on all media on which the Licensee Products are distributed and on the documentary form of each sub-license granted by the Licensee under clause 2.1.5:

"This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT®, was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO."
8.3.2 specify in all media on which any Licensee Product is distributed the version and date of the International Release contained in the Licensee Product.

8.4 The Licensee shall be entitled to use the "SNOMED" and "SNOMED CT" trade marks only on the Licensee Products distributed and modified in accordance with this License Agreement and any services relating thereto but not otherwise and subject to the trade mark utilization Regulation developed by the Licensor and published by the Licensor from time to time. All use by the Licensee of the "SNOMED" and "SNOMED CT" trade marks, and all goodwill resulting from that use, shall inure to the Licensor's benefit.

8.5 The Licensee shall maintain quality standards with respect to modifying, supplementing, marketing and distributing the Licensee Products, and any services relating thereto, that are in accordance with applicable law and are at least as stringent as the Regulations developed by the Licensor and published by the Licensor from time to time.

8.6 Upon reasonable written notice from the Licensor, the Licensee shall provide the Licensor with representative samples of materials, software products, advertising, agreements for use of the Licensee Products (other than the terms of those agreements that are unrelated to the Licensor's rights and obligations under this License Agreement) and/or other written materials relating to the Licensee's use of the International Release and the Licensor's trade marks to enable the Licensor reasonably to ascertain the Licensee's compliance with its obligations under this License Agreement. In the absence of circumstances giving the Licensor reasonable grounds to suspect a breach of this License Agreement, the Licensor may not give notice under this clause 8.6 more frequently than once per year.

8.7 If any use of the International Release (including without limitation use through a Licensee Product) is reasonably determined by the Licensor to be below the standards of quality required under this License Agreement, the Licensor shall notify the Licensee of such deficiency in writing. Upon receipt of such notice, the Licensee shall take all necessary steps to correct such deficiency (including such steps as the Licensor may reasonably specify).

8.8 The Licensee shall maintain a complete, accurate and up-to-date register of all sub-licenses granted by the Licensee under clause 2.1.5, and shall make that register available for inspection during normal business hours by the Licensor and its representatives upon the Licensee giving not less than fourteen (14) days' prior written notice. The register maintained by the Licensee under this clause 8.8 shall at a minimum contain the following information in respect of each sub-license: the name and registered office of the sub-licensee; the Licensee Product subject to the sub-license; and the version of the International Release included in that Licensee Product. In the absence of circumstances giving the Licensor reasonable grounds to suspect a breach of this License Agreement, the Licensor may not give notice under this clause 8.8 more frequently than once per year.

9. USE IN MEMBER TERRITORIES AND NON-MEMBER TERRITORIES

9.1 The Licensee may only exercise its rights under this License Agreement in a Member Territory in accordance with such conditions as the Member for that Member Territory may prescribe from time to time.

9.2 Conditions prescribed by a Member under clause 9.1 may:

9.2.1 include, without limitation, a requirement that the Licensee notify the Member before exercising its rights under this License Agreement in that Member's territory and a requirement that the Licensee enter into a license agreement with the Member in respect of that Member's National Release; and

9.2.2 relate to the International Release, the Member's National Release or any part of either of them.

9.3 The Licensee shall notify the Licensor (and, if the Licensee's registered office or principal place of business is situated in a Member Territory, shall also notify the Member for that Member Territory) in writing before exercising its rights under this License Agreement in any Non-Member Territory in respect of which the Licensee has not previously given notice under this clause 9.3. The notice shall be in such form and manner as the Licensor may prescribe from time to time, and shall include such information about the Licensee's current and proposed activities in that Non-Member Territory as the Licensor may require (but the Licensor may require only the same kinds of information as it requires to be provided by new Affiliates proposing to use, license or deploy the International Release or Licensee Products in Non-
9.4 In any case where the Licensee gives notice to a Member in accordance with clause 9.3, the Licensee consents to that Member providing the content of that notice to the Licensor.

9.5 For purposes of this clause 9, the Licensee exercises its rights under this License Agreement in any Member Territory or Non-Member Territory if, without limitation, it:

9.5.1 performs any act permitted by this License Agreement in that Member Territory or Non-Member Territory (as the case may be);

9.5.2 deploys the International Release (or any part of it) or any Licensee Product in that Member Territory or Non-Member Territory (as the case may be); or

9.5.3 distributes or licenses a Licensee Product for use in, or to any person who is situated in, that Member Territory or Non-Member Territory (as the case may be).

10 AFFILIATE STATUS

10.1 During the term of this License Agreement the Licensee shall be an Affiliate.

10.2 As an Affiliate, the Licensee shall be entitled to participate in the Licensor's Vendor Liaison Forum, which is a forum in which the Licensee and other Affiliates may communicate with the Licensor and with each other. The Licensor may make Regulations from time to time governing the Licensee's participation in the Vendor Liaison Forum. New Regulations that the Licensor shall make from time to time governing participation in the Vendor Liaison Forum shall not remove the Licensee's right to participate in that forum.

11. REPRESENTATIONS AND WARRANTIES

11.1 To the extent permitted by law, the Licensor excludes all representations, warranties and conditions that would otherwise be implied by law in this License Agreement (including, without limitation, all implied warranties of quality or fitness for a particular purpose).

11.2 Without limiting clause 11.1, the Licensor does not represent or warrant that the International Release or any part of it will satisfy any of the Licensee's requirements, operate in combinations selected by the Licensee or be free from defects or errors.

12. LIMITATION OF LIABILITY

12.1 The Licensor shall not be liable to the Licensee or to any other person, whether in contract, tort (including negligence), misrepresentation, breach of statutory duty or otherwise, for any of the following arising under or in connection with this License Agreement (including, without limitation, in respect of the Licensee's use of or inability to use the International Release or any part of it):

12.1.1 indirect or consequential loss;

12.1.2 special or punitive damages;

12.1.3 loss of profits, loss of savings and loss of revenue;

12.1.4 loss of business, loss of reputation and loss of goodwill; and

12.1.5 loss of data.

12.2 Neither the Licensor nor any Member shall be liable to the Licensee or any other person for any failure by the Licensor or the Member (as the case may be) to maintain or distribute any Extension (or part thereof) or Derivative
transferred to the Licensor or the Member (as the case may be) in accordance with clauses 3.4 or 3.5.

12.3 The liability of the Licensor arising in any year under or in connection with this License Agreement, whether in contract, tort (including negligence), misrepresentation, breach of statutory duty or otherwise, shall not in any event exceed the License Fees paid by the Licensee in respect of that year.

12.4 Nothing in this License Agreement excludes or limits the liability of either party for:

12.4.1 fraud (including fraudulent misrepresentation);

12.4.2 death or personal injury caused by the negligence of that party;

12.4.3 any breach of its obligations implied by section 12 of the Sale of Goods Act 1979; or

12.4.4 any other liability that by law cannot validly be excluded or limited (but only to the extent that the liability cannot validly be excluded or limited).

13. ASSIGNMENT

13.1 The Licensee may not assign, novate or otherwise transfer any of its rights or obligations under this License Agreement to any person without the prior written consent of the Licensor, not to be unreasonably withheld.

13.2 The Licensor may transfer all of its rights and obligations under this License Agreement to any person to whom the Licensor transfers the Intellectual Property Rights in respect of which the licenses under this License Agreement are granted.

14. GENERAL PROVISIONS

14.1 This License Agreement contains the entire agreement between the parties relating to the subject matter of this License Agreement, supersedes all previous agreements between the Parties relating to that subject matter and sets out the entirety of the Licensee's rights in respect of the International Release.

14.2 Each party acknowledges that, in entering into this License Agreement, it has not relied on any representation, warranty, collateral contract or other assurance made by or on behalf of the other party before the date of this License Agreement.

14.3 Except as provided in clause 6.3, this License Agreement may not be varied except in writing signed by both parties and expressed to vary this License Agreement.

14.4 Nothing in this License Agreement shall give either party the ability to act or incur obligations or liability on behalf of the other party or constitutes a joint venture, agency, partnership or employment relationship between the parties.

14.5 If any term of this License Agreement is or becomes illegal, invalid or unenforceable in any jurisdiction, that shall not affect the legality, validity or enforceability in that jurisdiction of any other term of this License Agreement, or the legality, validity or enforceability in any other jurisdiction of that or any other term of this License Agreement.

14.6 The Licensee agrees that the Licensor may appoint third parties to process personal data provided by the Licensee to the Licensor under or in connection with this License Agreement (including without limitation payment details provided in connection with the payment of License Fees). In connection with any such appointment, personal data provided by the Licensee may be transferred to, and processed in, a country outside the European Economic Area (EEA). The laws governing the processing of personal data may be less stringent in such a country than in the member countries of the EEA.

15. GOVERNING LAW AND JURISDICTION

15.1 This License Agreement shall be governed by, and construed in accordance with, English law.
15.2 The English courts shall have exclusive jurisdiction to settle any dispute arising out of or in connection with this License Agreement (including a dispute regarding its existence, validity or termination).

15.3 Clause 15.2 is for the benefit of the Licensor only. As a result, the Licensor shall not be prevented from taking proceedings relating to any dispute in any other courts with jurisdiction. To the extent permitted by law, the Licensor may take concurrent proceedings in any number of jurisdictions.

Appendix A

Defined Terms

In this License Agreement, the following defined terms have the following meanings:

<table>
<thead>
<tr>
<th>Term</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliate</td>
<td>an affiliate of the Licensor in accordance with the Licensor's Articles of Association;</td>
</tr>
<tr>
<td>Cross-Map</td>
<td>a work consisting of (i) SNOMED CT Content and (ii) content of another nomenclature, classification or knowledge structure, together with a set of relationships between (i) and (ii);</td>
</tr>
<tr>
<td>Data Analysis</td>
<td>a computer system that is used to analyze records or other data that is encoded using SNOMED CT, but not if that system is also a Data Creation System;</td>
</tr>
<tr>
<td>System</td>
<td></td>
</tr>
<tr>
<td>Data Creation</td>
<td>a computer system that is used to create records or other data that is encoded using SNOMED CT;</td>
</tr>
<tr>
<td>System</td>
<td></td>
</tr>
<tr>
<td>Derivative</td>
<td>a work consisting of (a) SNOMED CT Content, from the SNOMED CT CORE or an Extension; together with (b) either (i) additional properties and/or information about such SNOMED CT content; and/or (ii) any set of relationships between that SNOMED CT Content and content of other nomenclature, classification or knowledge structure, and includes a Cross-Map and a Sub-Set;</td>
</tr>
<tr>
<td>End User</td>
<td>a third party user of a Licensee Product;</td>
</tr>
<tr>
<td>Extension</td>
<td>a work consisting of SNOMED CT Content alone that is supplementary to the SNOMED CT Core and that depends on the SNOMED CT Core;</td>
</tr>
<tr>
<td>Hospital</td>
<td>a health care body or organisation providing secondary and/or tertiary care;</td>
</tr>
<tr>
<td>Intellectual</td>
<td>patents, trade marks, service marks, copyright(including rights in computer software), moral rights, database rights, rights in designs, trade secrets, know-how and other intellectual property rights, in each case whether registered or unregistered and including applications for registration, and all rights or forms of protection having equivalent or similar effect in any jurisdiction;</td>
</tr>
<tr>
<td>Property Rights</td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>the release produced and distributed by or on behalf of the Licensor, consisting of the SNOMED CT Core, the Specifications and the Licensor's Derivatives and other documents and software;</td>
</tr>
<tr>
<td>Release</td>
<td></td>
</tr>
<tr>
<td>License Fees</td>
<td>the license fees set out in Appendix B (License Fees in Non-Member Territories);</td>
</tr>
<tr>
<td>Licensee Products</td>
<td>products distributed or licensed by the Licensee that(1) include or interoperate with the International Release (or any part of it) and/or any Extensions or Derivatives created by the Licensee under this License Agreement, or (2) read or write records or other data that is encoded using SNOMED CT;</td>
</tr>
<tr>
<td>Member</td>
<td>a member of the Licensor;</td>
</tr>
<tr>
<td>Member</td>
<td></td>
</tr>
<tr>
<td><strong>Term</strong></td>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Territory</td>
<td>a territory that is represented by a Member (as published by the Licensor from time to time);</td>
</tr>
<tr>
<td>Namespace Identifier</td>
<td>a code or that part of a code that identifies the organization responsible for creating and maintaining a Standards-Based Extension or a Standards-Based Derivative and is used as an element of SNOMED CT Identifiers;</td>
</tr>
<tr>
<td>National Release</td>
<td>in respect of each Member, the release produced and distributed by the Member, consisting of the International Release, the Member's Extensions, the Member's Derivatives and other documents and software;</td>
</tr>
<tr>
<td>Non-Member Territory</td>
<td>a territory that is not a Member Territory;</td>
</tr>
<tr>
<td>Practice</td>
<td>(a) a single department of a Hospital (subject to paragraph 2.2 of Appendix B); or (b) any health care body or organization that provides principally primary care, including without limitation a pharmacy, an optician's facility, a physiotherapy centre, a general medical practice or a family medical practice;</td>
</tr>
<tr>
<td>Qualifying Research Project</td>
<td>a discrete research project that meets all of the following criteria: (a) it is supported by a formal proposal that has been peer reviewed; (b) it has been ethically approved in accordance with the prevailing legislation, regulations and guidelines in effect in the relevant territory; (c) it is conducted within a definite timeframe; (d) the results of the research are offered for publication in peer-reviewed public journals and are provided to the Licensor free of charge prior to publication;</td>
</tr>
<tr>
<td>Regulations</td>
<td>regulations made by the Licensor;</td>
</tr>
<tr>
<td>Relationship</td>
<td>a relationship, of a kind defined by the Licensor in Specifications, between concepts (which may be, without limitation, a hierarchical or an associative relationship) or between a concept and a description;</td>
</tr>
<tr>
<td>SNOMED CT</td>
<td>the concept-based work of clinical nomenclature and classification with multiple hierarchies and semantic definitions known as SNOMED Clinical Terms (SNOMED CT);</td>
</tr>
<tr>
<td>SNOMED CT Content</td>
<td>terminological content, consisting of concepts, descriptions and Relationships, each of which is identified using a SNOMED CT Identifier;</td>
</tr>
<tr>
<td>SNOMED CT Core</td>
<td>the SNOMED CT Content that is controlled, maintained and distributed by the Licensor from time to time;</td>
</tr>
<tr>
<td>SNOMED CT Identifier</td>
<td>a code, of a kind defined by the Licensor in Specifications, for identifying concepts, descriptions and Relationships;</td>
</tr>
<tr>
<td>Specification</td>
<td>specifications promulgated by the Licensor for products and processing relating to SNOMED CT, including specifications of the internal logic of SNOMED CT, editorial policies, guidelines and characteristics;</td>
</tr>
<tr>
<td>Sponsored Territory</td>
<td>a Non-Member Territory that has been recognized and designated by the Licensor as a sponsored territory (as published on the Licensor's web site);</td>
</tr>
<tr>
<td>Standard</td>
<td>a Specification that is formally adopted by the Licensor;</td>
</tr>
</tbody>
</table>
Standards-Based | in respect of an Extension or a Derivative, an Extension or Derivative the creation of which is the subject of one or more Standards; and
Sub-Set | a sub-set of SNOMED CT Content that is grouped together for one or more purposes.

Appendix B

License Fees in Non-Member Territories

1. Introduction

1.1 This Appendix B sets out the license fees payable by the Licensee in respect of its activities in Non-Member Territories.

1.2 The license fees set out in this Appendix B do not apply in respect of the Licensee's activities in any Non-Member Territory if that Non-Member Territory is a Sponsored Territory or was a Sponsored Territory at the time when the Licensee's activities in that Non-Member Territory were carried out.

1.3 The Licensor may, in its sole discretion, waive the Licensee's obligation to pay any or all of the license fees set out in this Appendix B if the Licensor considers that the Licensee's activities in any Non-Member Territory are in support of charitable or humanitarian causes in that Non-Member Territory. Any waiver by the Licensor under this paragraph 1.3 may be revoked by the Licensor at any time, shall be without prejudice to any of the Licensor's other rights and remedies under this License Agreement and shall not relieve the Licensee of any of its other obligations under this License Agreement.

1.4 Beginning in 2015, license fees payable by the Licensee in respect of its activities in Non-Member Territories for each financial year shall be adjusted by the same percentage as the General Assembly of the Licensor agrees to adjust the Aggregate Annual Fee (as defined in the Licensor's Articles of Association) relative to the Aggregate Annual Fee in the previous year.

1.5 The license fees in respect of Hospitals that are set out in this Appendix B apply only to Hospitals that are located on a single contiguous physical site. Any Hospital that is located on multiple physical sites shall be treated as falling within paragraph 4 of this Appendix B (and not within paragraphs 2 or 3).

1.6 For purposes of this Appendix B, if a Practice is located on multiple physical sites then each such site is treated as a separate Practice.

1.7 Notwithstanding anything else in this Appendix B, the deployment, distribution or licensing of any software that operates on a mobile device of any kind (including without limitation a mobile phone or tablet device), or any software or service that is accessed via the internet and enables users to extract or download any substantial portion of SNOMED CT, shall be treated as falling within paragraph 4 of this Appendix B (and not within paragraphs 2 or 3).

1.8 The Licensee's obligation to pay license fees in respect of any deployment of the International Release or any Licensee Product is not dependent on that deployment of the International Release or Licensee Product being used in a live or production environment.

1.9 In any case where the Licensee is exempt from the requirement to pay license fees by reason of a Licensee Product, a Data Analysis System or a Data Creation System being used exclusively in connection with a Qualifying Research Project, the Licensee shall report to the Licensor on the progress of that Qualifying Research Project in such manner as the Licensor may reasonably require. The Licensor may revoke the Licensee's exemption for Qualifying Research Projects provided in this Appendix B if the Licensee fails to comply with this paragraph 1.9.

2. Data Creation Systems
2.1 The Licensee shall pay the following fees in respect of each Hospital or Practice in a Non-Member Territory in or to which the Licensee:

(a) deploys the International Release (or any part of it) or any Licensee Product that contains the International Release (or any part of it) in a Data Creation System, unless that Data Creation System is used exclusively in connection with a Qualifying Research Project; or

(b) deploys, distributes or licenses a Licensee Product that is or includes a Data Creation System, unless that Licensee Product is used exclusively in connection with a Qualifying Research Project.

<table>
<thead>
<tr>
<th>Fee Band</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital in Band A Territory</td>
<td>US$ 1,954 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Hospital in Band B Territory</td>
<td>US$ 1,303 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Hospital in Band C Territory</td>
<td>US$ 652 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Practice in Band A, B or C Territory</td>
<td>US$ 652 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Hospital or Practice in Low Income Band</td>
<td>US $0 per annum baseline fee, adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Hospital or Practice in other territory</td>
<td>As per paragraph 5.2.</td>
</tr>
</tbody>
</table>

2.2 The total fees payable by the Licensee in respect of a number of Practices that are departments of a single Hospital shall not exceed the fee applicable to the Hospital itself. For purposes of this Appendix B, a Practice is treated as a department of a Hospital only if: (a) it is located on the premises of that Hospital; and (b) it is funded solely by that Hospital. In any case where either or both of the conditions in the preceding sentence are not met in respect of any Practice, fees shall be payable in respect of that Practice in addition to any fees that are payable in respect of any Hospital.

3. Data Analysis Systems

3.1 The Licensee shall pay the fees set out in paragraph 3.4 if the Licensee:

(a) deploys the International Release (or any part of it) or any Licensee Product that contains the International Release (or any part of it) in a Data Analysis System in a Non-Member Territory, unless that Data Analysis System is used exclusively in connection with a Qualifying Research Project; or

(b) deploys, distributes or licenses a Licensee Product that is or includes a Data Analysis System in a Non-Member Territory, unless that Licensee Product is used exclusively in connection with a Qualifying Research Project.

3.2 The fees set out in paragraph 3.4 apply in respect of each deployment, distribution or license of the International Release (or any part of it), a Licensee Product or a Data Analysis System, and vary according to the Non-Member Territory in which the deployment, distribution or licensing takes place.

3.3 If any Data Analysis System to which the fees in paragraph 3.4 apply consists of more than one database, the fees applicable to that Data Analysis System shall be multiplied by the number of databases in that Data Analysis System.

3.4 The fees under this paragraph 3 are as follows:

<table>
<thead>
<tr>
<th>Fee Band</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Band A Territory</td>
<td>US$ 1,954 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Band B Territory</td>
<td>US$ 1,303 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Band C Territory</td>
<td>US$ 652 per annum baseline fee adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Low Income Band</td>
<td>US $0 per annum baseline fee, adjusted as per paragraph 1.4</td>
</tr>
<tr>
<td>Other territory</td>
<td>As per paragraph 5.2.</td>
</tr>
</tbody>
</table>

4. **Other Activities**

4.1 The Licensee shall notify the Licensor in writing before deploying the International Release (or any part of it) or deploying, distributing or licensing any Licensee Product (in each case, other than exclusively in connection with Qualifying Research Projects) in, for use in, or to any person situated in, any Non-Member Territory in a manner that does not fall within paragraphs 2 to 3 of this Appendix B, explaining the Licensee's proposed activities.

4.2 Upon receiving notice from the Licensee under this paragraph 4, the Licensor may request, and the Licensee shall provide, such additional information in relation to the Licensee's proposed activities as the Licensor considers reasonably necessary to determine an appropriate license and reasonable fee in respect of the Licensee's proposed activities.

4.3 The Licensee shall be liable to pay such license fees as the Licensor may determine in accordance with this paragraph 4.

5. **Non-Member Territory Bandings**

5.1 The allocation of a Non-Member Territory into Band A, Band B, Band C, or Low Income Band shall be as determined by the Licensor (based on the Non-Member Territory's relative Gross National Income (GNI) or other measure adopted by the Licensor) and published by the Licensor on its web site.

5.2 The Licensee shall notify the Licensor in writing before carrying out any activity of a kind described in paragraphs 2 or 3 of this Appendix B in a Non-Member Territory that has not been allocated by the Licensor under paragraph 5.1. Upon receiving notice from the Licensee under this paragraph 5.2, the Licensor shall allocate the Non-Member Territory as described in paragraph 5.1.